


# Ozempic® Update: 0.25/0.5 mg dose pen will be delivered in a NEW 3 mL pen



To increase manufacturing flexibility, as of January 2024, the current **1.5 mL pen** which has delivered patients' 0.25/0.5 mg doses of Ozempic® will be **replaced by a new 3 mL pen**.

Since these larger 3 mL pens contain the same number of 0.25/0.5 mg doses as the current 1.5 mL pens (as shown in the table below), **prescribing Ozempic® 0.25/0.5 mg for your patients remains the same**.

NOTE: The current 1.5 mL pen (0.25/0.5 mg) will still be available while inventory remains.



## Same 0.25/0.5 mg doses. New, larger, 3 mL pen.

	CURRENT	NEW
	<p><b>Ozempic® 0.25/0.5 mg 1.5 mL pen</b></p>  <p>Short 1.5 mL cartridge</p>	<p><b>Ozempic® 0.25/0.5 mg 3 mL pen</b></p>  <p>Large 3 mL cartridge</p>
<b>QUANTITY</b>	1.5 mL (1 x 1.5 mL/pen)	3 mL (1 x 3 mL/pen)
<b>CONCENTRATION</b>	2 mg per 1.5 mL (1.34 mg/mL)	2 mg per 3 mL (0.68 mg/mL)
<b>NEW STARTS</b>	0.25 once weekly for 4 weeks, then 0.5 mg once weekly for 2 weeks (6 doses)	<b>SAME</b>
<b>MAINTENANCE</b>	0.5 mg once weekly for 4 weeks (4 doses)	<b>SAME</b>

**If you have any questions, please contact Novo Nordisk Customer Care (1-800-465-4334).**

Ozempic® (semaglutide injection) is indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control in combination with metformin, when diet and exercise plus maximal tolerated dose of metformin do not achieve adequate glycemic control.<sup>1</sup>

Consult the Ozempic® Product Monograph at [OzempicPM-E.ca](http://OzempicPM-E.ca) for more information relating to contraindications, warnings and precautions, conditions of clinical use, adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece.

The Product Monograph is also available by calling us at 1-800-465-4334.

**References:** 1. Ozempic® (semaglutide injection) Product Monograph. Novo Nordisk Canada Inc., August 4, 2023.



© 2024 Novo Nordisk Canada Inc.  
Ozempic® is a registered trademark of Novo Nordisk A/S and used under license by Novo Nordisk Canada Inc.  
Novo Nordisk Canada Inc., Tel: (905) 629-4222 or 1-800-465-4334. [www.novonordisk.ca](http://www.novonordisk.ca)

Pr **OZEMPIC**®  
semaglutide injection

CA230ZM00064E